Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SYRE Spyre Therapeutics, Inc. 8-K

Spyre reports $741M cash position, suspends at-the-market stock offering program

Filed April 13, 2026 · Period ending April 13, 2026 · ~1 min read

Key Changes

  • high

    Preliminary Q1 2026 cash position of ~$741M disclosed, though unaudited and subject to material change when final financials are released.

  • medium

    Company suspended its at-the-market equity offering, halting further stock sales under existing agreement until new registration documents are filed.

  • medium

    Q1 cash includes $30M from legacy asset sales, but $23M of that will be paid to contingent value rights holders in Q2, netting only $7M for operations.

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.

Partner

Trade SYRE commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify